If this message displays incorrectly, please view the web page |
||||||||||||||||
|
||||||||||||||||
INFECTIOUS DISEASES |
||||||||||||||||
GASTROENTEROLOGY Bile acid uptake inhibitors may prevent nonalcoholic fatty liver disease Drugs called ASBT inhibitors were successful in preventing nonalcoholic fatty liver disease in laboratory mice, suggesting they could be a useful clinical strategy for people. Nonalcoholic steatohepatitis (NASH) is an increasingly common liver disease linked to diet and obesity. It confers an elevated risk of type II diabetes and heart disease and can progress to cirrhosis. Read more... |
||||||||||||||||
INFECTIOUS DISEASES Vaccine may be achievable against many cold viruses at once The existence of more than 100 varieties of rhinovirus circulating globally has seemed like a daunting challenge for vaccine researchers. But by mixing together dozens of different inactivated cold viruses, researchers have developed a vaccine using neutralizing antibodies that can prevent infection in the laboratory and will soon be tested in human clinical trials. Read more... |
||||||||||||||||
RESEARCH FUNDING Annual Emory research funding tops $574.6 million Federal agencies awarded Emory researchers $389.7 million in FY16, including $333 million from the NIH, as Emory researchers attracted a total of $574.6 million, topping half a billion dollars for the seventh straight year. Funding was primarily health related, including for infectious diseases, Alzheimer's, environmental health, cardiology, nanotechnology, and immunotherapy. Read more... |
||||||||||||||||
Link to current issue | Archives | More Research News | Contact Us |
||||||||||||||||
Editor, Holly Korschun, Executive Director of Research Communications |
||||||||||||||||